Moderate revenue increase Actelion expected

Moderate increase Actelion expected

Over the past book year the analyst estimate the revenue to be around 2,1 billion Switzerland Franc. This is marginally more than the 2014's revenue of 1,96 billion Switzerland Franc. The consensus of the analysts for 2015 is a net profit of 675,82 million Switzerland Franc.

For 2015 the consensus of the earnings per share of Actelion is at profit of 5,67 Switzerland Franc. Based on this the price/earnings-ratio equals 24,22.

The consensus of the dividends per share is at 1,5 Switzerland Franc.Consequently the dividend return is around 1,09 percent. On average the stocks in this sector yield a dividend return of around 0,54 percent.

The stock Actelion is covered by 10 analysts. The average target price for Actelion is at 141,10 Switzerland Franc. This is 6 percent more than the current stock price of 137,30 Switzerland Franc.

The stocks Mithra, Kiadis and Shire in the sector pharmaceutical sector have the most buy recommendations. The 3 most recent recommendations for the pharmaceutical sector were provided by HSBC (buy, 155,00 Switzerland Franc), Berenberg (hold, 143,00 Switzerland Franc) and Deutsche Bank (hold, 180,00 Switzerland Franc).

Actelion's book value/price equals 0,13. The pharmaceutical company now trades at a Shiller PE of 20.22. The stock now trades at 137,30 Switzerland Franc. This equals 27 times the 2014's earnings per share.